Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Capital Expenditures for 9 consecutive years, with -$8.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 17.14% to -$8.0 million in Q4 2025 year-over-year; TTM through Sep 2025 was -$1.6 million, a 109.41% decrease, with the full-year FY2024 number at $1.2 million, down 90.79% from a year prior.
  • Capital Expenditures was -$8.0 million for Q4 2025 at Denali Therapeutics, down from -$1.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.9 million in Q2 2025 to a low of -$9.6 million in Q4 2024.
  • A 5-year average of $809400.0 and a median of $1.6 million in 2022 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 17293.33% in 2021; the steepest drop was 258.47% in 2021.
  • Denali Therapeutics' Capital Expenditures stood at -$4.9 million in 2021, then surged by 124.31% to $1.2 million in 2022, then soared by 468.56% to $6.7 million in 2023, then tumbled by 243.51% to -$9.6 million in 2024, then increased by 17.14% to -$8.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Capital Expenditures are -$8.0 million (Q4 2025), -$1.4 million (Q3 2025), and $8.9 million (Q2 2025).